Literature DB >> 10980604

A link between basic fibroblast growth factor (bFGF) and EWS/FLI-1 in Ewing's sarcoma cells.

L Girnita1, A Girnita, M Wang, J M Meis-Kindblom, L G Kindblom, O Larsson.   

Abstract

The EWS/FLI-1 fusion gene is characteristic of most cases of Ewing's sarcoma and has been shown to be crucial for tumor transformation and cell growth. In this study we demonstrate a drastic down-regulation of the EWS/FLI-1 protein, and a growth arrest, following serum depletion of Ewing's sarcoma cells. This indicates that growth factor circuits may be involved in regulation of the fusion gene product. Of four different growth factors tested, basic fibroblast growth factor (bFGF) was found to be of particular significance. In fact, upon treatment of serum-depleted cells with bFGF, expression of the EWS/FLI-1 protein and growth of the Ewing's sarcoma cells were restored. In addition, a bFGF-neutralizing antibody, which was confirmed to inhibit FGF receptor (FGFR) phosphorylation, caused down-regulation of EWS/FLI-1. Experiments using specific cell cycle blockers (thymidine and colcemide) suggest that EWS/FLI-1 is directly linked to bFGF stimulation, and not indirectly to cell proliferation. We also demonstrated expression of FGFRs in several tumor samples of Ewing's sarcoma. Taken together, our data suggest that expression of FGFR is a common feature of Ewing's sarcoma and, in particular, that the bFGF pathway may be important for the maintenance of a malignant phenotype of Ewing's sarcoma cells through up-regulating the EWS/FLI-1 protein. Oncogene (2000) 19, 4298 - 4301

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10980604     DOI: 10.1038/sj.onc.1203755

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  18 in total

1.  The EWS/FLI Oncogene Drives Changes in Cellular Morphology, Adhesion, and Migration in Ewing Sarcoma.

Authors:  Aashi Chaturvedi; Laura M Hoffman; Alana L Welm; Stephen L Lessnick; Mary C Beckerle
Journal:  Genes Cancer       Date:  2012-02

Review 2.  The emerging role of mammalian target of rapamycin inhibitors in the treatment of sarcomas.

Authors:  Sushma Vemulapalli; Alain Mita; Yesid Alvarado; Kamalesh Sankhala; Monica Mita
Journal:  Target Oncol       Date:  2011-04-28       Impact factor: 4.493

3.  Basic fibroblast growth factor in the bone microenvironment enhances cell motility and invasion of Ewing's sarcoma family of tumours by activating the FGFR1-PI3K-Rac1 pathway.

Authors:  S Kamura; Y Matsumoto; J-I Fukushi; T Fujiwara; K Iida; Y Okada; Y Iwamoto
Journal:  Br J Cancer       Date:  2010-07-06       Impact factor: 7.640

Review 4.  Molecular genetics of pediatric soft tissue tumors: clinical application.

Authors:  Chung-Che Chang; Vinod B Shidham
Journal:  J Mol Diagn       Date:  2003-08       Impact factor: 5.568

Review 5.  Clinical relevance of molecular genetics to paediatric sarcomas.

Authors:  Olga Slater; Janet Shipley
Journal:  J Clin Pathol       Date:  2007-04-27       Impact factor: 3.411

Review 6.  New developments in mammalian target of rapamycin inhibitors for the treatment of sarcoma.

Authors:  Mark Agulnik
Journal:  Cancer       Date:  2011-08-11       Impact factor: 6.860

7.  Insulin-like growth factor 1 receptor as a therapeutic target in ewing sarcoma: lack of consistent upregulation or recurrent mutation and a review of the clinical trial literature.

Authors:  Alison O'Neill; Nilay Shah; Naamah Zitomersky; Marc Ladanyi; Neerav Shukla; Aykut Uren; David Loeb; Jeffrey Toretsky
Journal:  Sarcoma       Date:  2013-01-28

8.  PI3K/AKT is involved in mediating survival signals that rescue Ewing tumour cells from fibroblast growth factor 2-induced cell death.

Authors:  M Hotfilder; P Sondermann; A Senss; F van Valen; H Jürgens; J Vormoor
Journal:  Br J Cancer       Date:  2005-02-28       Impact factor: 7.640

9.  Factors Affecting EWS-FLI1 Activity in Ewing's Sarcoma.

Authors:  David Herrero-Martin; Argyro Fourtouna; Stephan Niedan; Lucia T Riedmann; Raphaela Schwentner; Dave N T Aryee
Journal:  Sarcoma       Date:  2011-11-10

10.  Targeted therapies in sarcomas: challenging the challenge.

Authors:  Juan Martín Liberal; Laura Lagares-Tena; Miguel Sáinz-Jaspeado; Silvia Mateo-Lozano; Xavier García Del Muro; Oscar M Tirado
Journal:  Sarcoma       Date:  2012-06-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.